Real world data shows treatment advantages of Trulicity over once-daily liraglutide and once-weekly exenatide QW for type 2 diabetes, Eli Lilly.
People with type 2 diabetes new to treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist (RA) had better blood sugar control, were more likely to adhere to treatment and stayed on treatment longer with once-weekly Trulicity (dulaglutide) compared to once-daily liraglutide and once-weekly exenatide QW according to real-world data. These data are being presented at the American Diabetes Association's (ADA) 78th Scientific Sessions in Orlando.
Trulicity is Eli Lilly and Company's once-weekly, injectable GLP-1 RA approved to improve blood sugar (glucose) in adults with type 2 diabetes. Trulicity is available in 0.75 mg and 1.5 mg and should be used along with diet and exercise. Qing Huang, PhD, associate director and principal investigator from HealthCore, Inc,.stated "These real-world data show that people starting on once-weekly Trulicity are associated with a higher likelihood of adhering to their treatment regimen and having a lower A1C compared to two other GLP-1 RA options.",/p>
The retrospective observational study used U.S. claims data of people with type 2 diabetes newly prescribed Trulicity or either liraglutide or exenatide QW to compare how these treatments performed in a real-world setting. People were matched against key characteristics such as age, gender, location and baseline A1C to ensure balance in comparing the groups. Trulicity consistently showed advantages across all measures, including A1C reductions, adherence (taking treatment as prescribed) and persistence (staying on treatment). After both six months and one year of treatment, Trulicity provided significantly better glycemic control than liraglutide (mean absolute reduction in A1C in percent): Six months: -1.10 percent (Trulicity), -0.86 percent (liraglutide). One year: -0.98 percent (Trulicity), -0.77 percent (liraglutide). After six months and one year of treatment, Trulicity led to better glycemic control than exenatide QW (mean absolute reduction in A1C in percent): Six months: -1.15 percent (Trulicity), -0.92 percent (exenatide QW). One year: -1.00 percent (Trulicity), -0.77 percent (exenatide QW).
After one year, people taking Trulicity were significantly more likely to follow their treatment regimen and less likely to discontinue treatment than with liraglutide or exenatide QW. People taking Trulicity had significantly lower rates of discontinuing treatment than those taking liraglutide or exenatide QW.
Trulicity vs. liraglutide: Adherence: 51.2 percent (Trulicity), 38.2 percent (liraglutide). Persistence: 252.8 days (Trulicity), 218.2 days (liraglutide). Patients who discontinued treatment: 45.0 percent (Trulicity), 56.2 percent (liraglutide).
Trulicity vs. exenatide QW : Adherence: 50.7 percent (Trulicity), 31.9 percent (exenatide QW). Persistence: 251.4 days (Trulicity), 192.5 days (exenatide QW). Patients who discontinued treatment: 45.1 percent (Trulicity), 65.6 percent (exenatide QW).
Related news and insights
Anavex Life Sciences Corp. announced positive topline results from its Phase IIb/III ANAVEX2-73-AD-004 clinical trial of oral ANAVEX2 73 (blarcamesine) for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD).
Vaxxinity announced today that its next generation UB 612 COVID-19 vaccine, when administered as a single heterologous booster dose, elicited strong neutralizing antibodies against SARS-CoV-2 when compared head-to-head to three globally authorized platform vaccines administered as homologous boosters, confirming success in meeting the primary and key secondary immunogenicity endpoints of its pivotal global Phase III trial.